Andrew Cittadine
CIK: 0001863624
Transaction Breakdown
High conviction signal
Position reduction
Derivative conversions
Compensation grants
Gifts, tax withholding, conversions, dispositions to the issuer and other codes
Companies & Roles (1)
Monopar Therapeutics
Discretionary Trading P&L
Holdings
Transaction History (23 total)
- Sep 30, 2026MNPR
Monopar Therapeutics
Exercise(M)Direct4.4K shares- - Sep 30, 2026MNPR
Monopar Therapeutics
Tax Payment(F)Direct1.9K shares at avg. $79.67$155K - Jun 30, 2026MNPR
Monopar Therapeutics
Exercise(M)Direct5.3K shares- - Jun 30, 2026MNPR
Monopar Therapeutics
Tax Payment(F)Direct2.3K shares at avg. $92.59$214K - Mar 31, 2026MNPR
Monopar Therapeutics
Tax Payment(F)Direct1.6K shares at avg. $54.79$86K - Mar 31, 2026MNPR
Monopar Therapeutics
Exercise(M)Direct3.5K shares- - Dec 31, 2025MNPR
Monopar Therapeutics
Exercise(M)Direct4.3K shares- - Dec 31, 2025MNPR
Monopar Therapeutics
Tax Payment(F)Direct1.9K shares at avg. $65.30$123K - Dec 2, 2025MNPR
Monopar Therapeutics
Award(A)DirectRestricted Stock Units
13.9K shares- - Dec 2, 2025MNPR
Monopar Therapeutics
Award(A)DirectStock Options
9K shares- - Sep 30, 2025MNPR
Monopar Therapeutics
Exercise(M)Direct4.3K shares- - Sep 30, 2025MNPR
Monopar Therapeutics
Tax Payment(F)Direct1.9K shares at avg. $81.67$155K - Jun 30, 2025MNPR
Monopar Therapeutics
Exercise(M)Direct6.9K shares- - Jun 30, 2025MNPR
Monopar Therapeutics
Tax Payment(F)Direct3K shares at avg. $35.78$107K - Mar 31, 2025MNPR
Monopar Therapeutics
Tax Payment(F)Direct744 shares at avg. $36.41$27K - Mar 31, 2025MNPR
Monopar Therapeutics
Exercise(M)Direct1.8K shares- - Mar 4, 2025MNPR
Monopar Therapeutics
Award(A)DirectRestricted Stock Units
40.6K shares- - Mar 4, 2025MNPR
Monopar Therapeutics
Award(A)DirectStock Options
43.4K shares- - Dec 31, 2024MNPR
Monopar Therapeutics
Exercise(M)Direct1.8K shares- - Dec 31, 2024MNPR
Monopar Therapeutics
Tax Payment(F)Direct721 shares at avg. $22.00$16K - Sep 30, 2024MNPR
Monopar Therapeutics
Tax Payment(F)Direct535 shares at avg. $6.74$4K - Sep 30, 2024MNPR
Monopar Therapeutics
Exercise(M)Direct1.8K shares- - Mar 31, 2024MNPR
Monopar Therapeutics
Exercise(M)DirectRestricted Stock Units
1.8K shares-
| Type | Shares | Price | Ownership | |||
|---|---|---|---|---|---|---|
| Sep 30, 2026 | MNPR Monopar Therapeutics | Exercise(M) | 4,384 | - | $0 | Direct |
| Sep 30, 2026 | MNPR Monopar Therapeutics | Tax Payment(F) | 1,944 | $79.67 | $154,878 | Direct |
| Jun 30, 2026 | MNPR Monopar Therapeutics | Exercise(M) | 5,254 | - | $0 | Direct |
| Jun 30, 2026 | MNPR Monopar Therapeutics | Tax Payment(F) | 2,309 | $92.59 | $213,790 | Direct |
| Mar 31, 2026 | MNPR Monopar Therapeutics | Tax Payment(F) | 1,571 | $54.79 | $86,075 | Direct |
| Mar 31, 2026 | MNPR Monopar Therapeutics | Exercise(M) | 3,514 | - | $0 | Direct |
| Dec 31, 2025 | MNPR Monopar Therapeutics | Exercise(M) | 4,326 | - | $0 | Direct |
| Dec 31, 2025 | MNPR Monopar Therapeutics | Tax Payment(F) | 1,889 | $65.30 | $123,352 | Direct |
| Dec 2, 2025 | MNPR Monopar Therapeutics | Award(A) Restricted Stock Units | 13,919 | - | - | Direct |
| Dec 2, 2025 | MNPR Monopar Therapeutics | Award(A) Stock Options | 8,969 | - | - | Direct |
| Sep 30, 2025 | MNPR Monopar Therapeutics | Exercise(M) | 4,327 | - | - | Direct |
| Sep 30, 2025 | MNPR Monopar Therapeutics | Tax Payment(F) | 1,896 | $81.67 | $154,846 | Direct |
| Jun 30, 2025 | MNPR Monopar Therapeutics | Exercise(M) | 6,863 | - | - | Direct |
| Jun 30, 2025 | MNPR Monopar Therapeutics | Tax Payment(F) | 2,990 | $35.78 | $106,982 | Direct |
| Mar 31, 2025 | MNPR Monopar Therapeutics | Tax Payment(F) | 744 | $36.41 | $27,089 | Direct |
| Mar 31, 2025 | MNPR Monopar Therapeutics | Exercise(M) | 1,791 | - | - | Direct |
| Mar 4, 2025 | MNPR Monopar Therapeutics | Award(A) Restricted Stock Units | 40,581 | - | - | Direct |
| Mar 4, 2025 | MNPR Monopar Therapeutics | Award(A) Stock Options | 43,445 | - | - | Direct |
| Dec 31, 2024 | MNPR Monopar Therapeutics | Exercise(M) | 1,790 | - | $0 | Direct |
| Dec 31, 2024 | MNPR Monopar Therapeutics | Tax Payment(F) | 721 | $22.00 | $15,862 | Direct |
| Sep 30, 2024 | MNPR Monopar Therapeutics | Tax Payment(F) | 535 | $6.74 | $3,606 | Direct |
| Sep 30, 2024 | MNPR Monopar Therapeutics | Exercise(M) | 1,791 | - | $0 | Direct |
| Mar 31, 2024 | MNPR Monopar Therapeutics | Exercise(M) Restricted Stock Units | 1,791 | - | - | Direct |
1-23 of 23 transactions
About Cittadine Andrew
Cittadine Andrew (SEC CIK 0001863624) files insider reports with the SEC as Chief Operating Officer of Monopar Therapeutics (MNPR).
Signal8 holds 11 ownership filings by Cittadine Andrew, all Form 4s, filed between Oct 2, 2024 and Oct 2, 2026. Those filings report 23 transactions, from Mar 31, 2024 to Sep 30, 2026. Signal8's Form 4 history starts in Sep 2024.
The business address on Cittadine Andrew's filings is in WILMETTE, IL.
Recent filings by Cittadine Andrew
- Sep 30, 2026: Option exercise of MNPR shares (Form 4, code M).
- Sep 30, 2026: Tax withholding of MNPR shares (Form 4, code F).
- Jun 30, 2026: Option exercise of MNPR shares (Form 4, code M).
- Jun 30, 2026: Tax withholding of MNPR shares (Form 4, code F).
- Mar 31, 2026: Tax withholding of MNPR shares (Form 4, code F).
Other insiders filing for Monopar Therapeutics (MNPR)
- Robinson Chandler, Chief Executive Officer
- STARR CHRISTOPHER M, Director
- Vu Quan Anh, Chief Financial Officer
- Tsuchimoto Kim R, Director
- Anderson Raymond, Director
- RIOUX PATRICE, Officer